Cells capture intracellular proteins and organelles by the process of macroautophagy (autophagy hereafter), which delivers them to lysosomes where they are degraded. The breakdown products of autophagy cargo such as amino acids, sugars, nucleosides and lipids, are released from lysosomes into the cytoplasm where they are reused. Autophagy thereby recycles intracellular components to sustain cell and organism metabolism and survival in starvation, a function conserved from yeast to mammals. Autophagy is also a mechanism for eliminating cellular waste such as damaged proteins and organelles, particularly mitochondria, the accumulation of which is toxic. This protein and organelle quality control function of autophagy is also highly conserved and required for homeostasis. Autophagy levels are normally low, but are dramatically induced by starvation and stress to facilitate cellular adaptation. Cancer cells also rely on autophagy, but more so than normal cells. This may be due to high metabolic demand imposed by cancer cell growth and residence in a stressful microenvironment. In contrast to normal cells, cancer cells often have autophagy induced under fed conditions. For example, Ras-driven cancers commonly have high levels of basal autophagy and are extremely dependent on autophagy for sustaining mitochondrial respiration, for survival in stress and for tumorigenesis. Thus, in comparison to normal cells, some cancers may be addicted to autophagy and preferentially sensitive to autophagy inhibition, prompting interest in inhibiting autophagy to improve cancer therapy. Precisely how autophagy supports cancer growth and survival, the extent to which normal tissues and tumors are differentially affected, and the most effective means is to implement this concept in the clinic, remain open questions. To address these questions we examined the role of autophagy using genetically engineered mouse models (GEMMs) for K-rasG12D-driven non-small-cell lung cancer (NSCLC) and B-rafV600E- driven lung cancer. We found that deficiency in the essential autophagy gene atg7 causes tumor cells to accumulate large numbers of defective mitochondria and undergo atrophy. Atg7 deficiency also diverts progression of lung adenomas and carcinomas to oncocytomas. Oncocytomas are rare, predominantly benign neoplasms that arise in epithelial tissues that are characterized by the accumulation of large numbers of respiration-defective, mutant mitochondria. This discovery revealed for the first time that autophagy is a cancer fate determinant, that autophagy defects may be the molecular basis for the genesis of oncocytomas, and that oncocytomas can derive from adenomas and carcinomas when autophagy is impaired. We will test the central hypothesis that autophagy defects are the molecular basis for the genesis of oncocytomas. We will determine if atg7 deficiency produces mitochondrial genome mutations that convert carcinomas to oncocytomas, if mutations in essential autophagy genes cause human oncocytomas, and if producing oncocytomas by knocking out autophagy creates sensitivity to metabolic stress, enhancing cancer therapy.
We have known for over 50 years that a major feature that distinguishes normal cells from cancer cells is altered metabolism. Only recently has it become clear that oncogenic events reprogram metabolism to generate the building blocks for production of new tumor cells and to meet the energy requirements for cancer cell growth. We now know that tumor cells can cannibalize their own intracellular proteins and organelles and recycle them through the process of autophagy to sustain metabolism and survival in stress and starvation. We now also know that autophagy inhibition impairs tumor cell survival, but more importantly causes aggressive carcinomas to be converted into more benign oncocytomas. This suggests that autophagy defects are the molecular basis for the genesis of oncocytomas and that the conversion of carcinomas to oncocytomas is the mechanism by which autophagy inhibition can suppress tumor growth. Exploiting this novel process to improve cancer therapy is truly an exciting new opportunity.
|Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30|
|White, Eileen (2016) Autophagy and p53. Cold Spring Harb Perspect Med 6:a026120|
|Santanam, Urmila; Banach-Petrosky, Whitney; Abate-Shen, Cory et al. (2016) Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev 30:399-407|
|Lashinger, Laura M; O'Flanagan, Ciara H; Dunlap, Sarah M et al. (2016) Starving cancer from the outside and inside: separate and combined effects of calorie restriction and autophagy inhibition on Ras-driven tumors. Cancer Metab 4:18|
|(2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222|
|Zong, Wei-Xing; Rabinowitz, Joshua D; White, Eileen (2016) Mitochondria and Cancer. Mol Cell 61:667-76|
|Kumar, Namit; Srivillibhuthur, Manasa; Joshi, Shilpy et al. (2016) A YY1-dependent increase in aerobic metabolism is indispensable for intestinal organogenesis. Development 143:3711-3722|
|Guo, Jessie Yanxiang; Teng, Xin; Laddha, Saurabh V et al. (2016) Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. Genes Dev 30:1704-17|
|Xie, Xiaoqi; Koh, Ju Yong; Price, Sandy et al. (2015) Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov 5:410-23|
|Joshi, Shilpy; Tolkunov, Denis; Aviv, Hana et al. (2015) The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep 13:1895-908|
Showing the most recent 10 out of 56 publications